Engineered nano-bacteria hybrids for precision cancer immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Nanotechnology
• Microbiology

Background:

• Bacterial therapy offers a promising approach to precision cancer immunotherapy.
• Bacteria possess inherent tumor-homing abilities, immunostimulatory properties, and engineering flexibility.
• Conventional cancer treatments face limitations that bacterial therapy aims to address.

Purpose of the Study:

• To review recent advances in integrating nanotechnology with bacterial systems for precision cancer immunotherapy.
• To highlight the development and therapeutic utility of nano-bacteria hybrids and bacterial-derived components.
• To explore strategies for overcoming current limitations and advancing clinical translation.

Main Methods:

• Discussion of nano-bacteria hybrid construction strategies (physical, chemical, biological interfaces).
• Review of therapeutic applications of bacterial-derived components: outer membrane vesicles (OMVs), bacterial ghosts (BGs), and gas vesicles (GVs).
• Exploration of synergistic integration with immune checkpoint blockade, CAR-T cell therapy, and genetic engineering.

Main Results:

• Development of multifunctional nano-bacteria hybrids through various interface strategies.
• Demonstration of therapeutic utility of bacterial-derived components like OMVs, BGs, and GVs.
• Synergistic effects observed when combining nano-bacteria hybrids with immunotherapies and genetic engineering.

Conclusions:

• Nano-bacteria hybrids represent a significant advancement in precision cancer immunotherapy.
• Integration with other therapies enhances drug delivery, modulates the tumor microenvironment, and boosts immune activation.
• Future research should focus on overcoming challenges like tumor heterogeneity, immunosuppression, and safety for clinical translation.